eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
eXoZymes (NASDAQ: EXOZ) has appointed Damien Perriman as Chief Commercial Officer (CCO) in a newly created role. Perriman brings over 20 years of experience in commercializing biotechnologies across nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals markets.
Previously holding commercial leadership positions at Genomatica (Geno) and Gevo, Perriman also serves as Chairman of Danish biotech startup Cellugy. The appointment aligns with eXoZymes' strategic focus on scaling and commercializing biosolutions for sustainable feedstock transformation into essential chemicals, medicines, and biofuels.
The company will discuss this appointment during their Q4 and full-year 2024 results conference call scheduled for 4:30 PM Eastern / 1:30 PM Pacific.
eXoZymes (NASDAQ: EXOZ) ha nominato Damien Perriman come Chief Commercial Officer (CCO) in un ruolo appena creato. Perriman porta con sé oltre 20 anni di esperienza nella commercializzazione di biotecnologie nei settori dell'alimentazione, della cura personale, della plastica, dei tessuti, delle fragranze, dei carburanti ad alte prestazioni e dei prodotti chimici speciali.
In precedenza, ha ricoperto posizioni di leadership commerciale presso Genomatica (Geno) e Gevo, e attualmente è Presidente della startup biotech danese Cellugy. Questa nomina si allinea con l'obiettivo strategico di eXoZymes di espandere e commercializzare biosoluzioni per la trasformazione sostenibile delle materie prime in sostanze chimiche essenziali, medicinali e biocarburanti.
L'azienda discuterà di questa nomina durante la loro conferenza telefonica sui risultati del quarto trimestre e dell'intero anno 2024, programmata per le 16:30 ora orientale / 13:30 ora del Pacifico.
eXoZymes (NASDAQ: EXOZ) ha nombrado a Damien Perriman como Director Comercial (CCO) en un nuevo puesto creado. Perriman aporta más de 20 años de experiencia en la comercialización de biotecnologías en los mercados de nutrición, cuidado personal, plásticos, textiles, fragancias, combustibles de alto rendimiento y productos químicos especiales.
Anteriormente ocupó puestos de liderazgo comercial en Genomatica (Geno) y Gevo, y actualmente es Presidente de la startup biotecnológica danesa Cellugy. La nombramiento se alinea con el enfoque estratégico de eXoZymes en escalar y comercializar biosoluciones para la transformación sostenible de materias primas en productos químicos esenciales, medicamentos y biocombustibles.
La empresa discutirá esta nombramiento durante su conferencia telefónica sobre los resultados del cuarto trimestre y del año completo 2024, programada para las 4:30 PM hora del Este / 1:30 PM hora del Pacífico.
eXoZymes (NASDAQ: EXOZ)는 Damien Perriman을 신설된 최고 상업 책임자(Chief Commercial Officer, CCO)로 임명했습니다. Perriman은 영양, 개인 관리, 플라스틱, 섬유, 향수, 성능 연료 및 특수 화학 시장에서 생명공학 상용화에 20년 이상의 경험을 가지고 있습니다.
이전에는 Genomatica (Geno)와 Gevo에서 상업적 리더십 직책을 맡았으며, 현재 덴마크 생명공학 스타트업 Cellugy의 회장을 역임하고 있습니다. 이 임명은 eXoZymes가 지속 가능한 원료 변환을 위한 바이오 솔루션의 확장 및 상용화에 전략적으로 집중하고 있음을 반영합니다.
회사는 2024년 4분기 및 전체 연도 실적 발표 전화 회의에서 이 임명에 대해 논의할 예정이며, 회의는 동부 표준시 기준 오후 4시 30분 / 태평양 표준시 기준 오후 1시 30분에 진행됩니다.
eXoZymes (NASDAQ: EXOZ) a nommé Damien Perriman au poste de Directeur Commercial (CCO) dans un nouveau rôle créé. Perriman apporte plus de 20 ans d'expérience dans la commercialisation des biotechnologies dans les secteurs de la nutrition, des soins personnels, des plastiques, des textiles, des parfums, des carburants de performance et des produits chimiques spéciaux.
Auparavant, il a occupé des postes de direction commerciale chez Genomatica (Geno) et Gevo, et il est également président de la startup biotechnologique danoise Cellugy. Cette nomination s'inscrit dans l'orientation stratégique d'eXoZymes visant à développer et commercialiser des biosolutions pour la transformation durable des matières premières en produits chimiques essentiels, médicaments et biocarburants.
L'entreprise discutera de cette nomination lors de sa conférence téléphonique sur les résultats du quatrième trimestre et de l'année 2024, prévue à 16h30 heure de l'Est / 13h30 heure du Pacifique.
eXoZymes (NASDAQ: EXOZ) hat Damien Perriman zum Chief Commercial Officer (CCO) in einer neu geschaffenen Position ernannt. Perriman bringt über 20 Jahre Erfahrung in der Kommerzialisierung von Biotechnologien in den Bereichen Ernährung, Körperpflege, Kunststoffe, Textilien, Düfte, Hochleistungsbrennstoffe und Spezialchemikalien mit.
Vorher hatte er Führungspositionen im Vertrieb bei Genomatica (Geno) und Gevo inne und ist derzeit Vorsitzender des dänischen Biotech-Startups Cellugy. Die Ernennung passt zu eXoZymes strategischem Fokus auf die Skalierung und Kommerzialisierung von Biosolutions zur nachhaltigen Umwandlung von Rohstoffen in essentielle Chemikalien, Medikamente und Biokraftstoffe.
Das Unternehmen wird diese Ernennung während ihrer Telefonkonferenz zu den Ergebnissen des vierten Quartals und des gesamten Jahres 2024 besprechen, die für 16:30 Uhr Eastern / 13:30 Uhr Pacific angesetzt ist.
- Strategic expansion of leadership team with experienced executive
- New CCO brings 20+ years of relevant industry experience
- Addition supports commercial growth and partnership development
- Newly created role may increase operational expenses
Expanded leadership team as eXoZymes ramps up commercial growth
Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies
Focus on developing commercial opportunities, spin-outs, joint-ventures, and licensing deals with future partners
Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO).
Perriman brings more than two decades of experience in successfully commercializing several biotechnologies, spanning diverse markets such as nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals. Before joining eXoZymes, Perriman most recently has served leading commercial roles at both Genomatica (Geno) and Gevo, while also serving as Chairman of the Board of Danish biotechnology startup Cellugy.
“eXoZymes represents the new generation of SynBio design and scale-up, setting new standards for development speed and opening a range of commercially compelling product opportunities. This new approach can overcome process titer constraints and the feedstock limitations of conventional technologies, enabling projects to reach commercial scale sooner and with lower capital risk. This sets us up to be an innovative and reliable solutions provider for companies looking to make greater impact with more sustainable and globally competitive products,” states Chief Commercial Officer at eXoZymes, Damien Perriman, and continues, “We are stepping into an exciting future, commercializing the next generation of biomanufacturing.”
Video presentation of Damien Perriman available here.
“Damien Perriman represents the kind of formidable talent, experience, values and diverse set of capabilities we’re investing in to develop our company and the next generation of biomanufacturing,” states Michael Heltzen, CEO of eXoZymes, and adds, “The hire of Damien reflects our strategic focus on scaling and commercializing biosolutions, in close collaboration with our upcoming partners, across multiple sectors.”
Conference call at 4:30 Eastern today
On today’s conference call to discuss results for the fourth quarter and full year 2024 at 4:30 PM Eastern / 1:30PM Pacific, there will also be a possibility to ask questions around this hire. Investors and interested parties can access the live webinar, at the time of the event through eXoZymes' investor relations website. A recording of the conference call will also be made publicly available soon after the live call.
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to engineer, control and optimize nature’s own natural processes to produce chemical compounds, enabling the company’s partners to replace traditional chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the logical successor to most SynBio projects.
While the company, eXoZymes Inc., has introduced “exozymes” as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more on exozymes.com.
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of eXoZymes’ quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
Investor relations contact
Email: ir@exozymes.com
eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
FAQ
What experience does Damien Perriman bring to EXOZ as the new CCO?
What markets has EXOZ's new CCO Damien Perriman worked in previously?
What will be Damien Perriman's main focus areas as EXOZ's CCO?
When will EXOZ discuss their Q4 and full-year 2024 results?
